Background Post-acute sequelae of COVID-19 (PASC) produce significant morbidity,
prompting evaluation of interventions that might lower risk. Selective serotonin reuptake …

Objective To examine differences in mortality and/or severe acute respiratory syndrome
between selective serotonin reuptake inhibitor-(SSRI) users and non-SSRI users up to 60 …

Abstract Background and Aim Due to the high social and economic burden and also
mortality and morbidity caused by coronavirus disease 2019 (COVID‐19) in the past few …

Importance Antidepressant use may be associated with reduced levels of several
proinflammatory cytokines suggested to be involved with the development of severe COVID …

Abstract The World Health Organization has proposed that a search be made for alternatives
to vaccines for the prevention and treatment of COVID-19, with one such alternative being …

The article COVID-19 mortality among selective serotonin reuptake inhibitor usersdresults
from a nationwide cohort, by Stauning MA et al.[1], in this journal, is based on an analysis of …

Purpose The absence of specific treatments for COVID-19 leads to an intense global effort in
the search for new therapeutic interventions and better clinical outcomes for patients. This …

Background The efficacy of selective serotonin reuptake inhibitors (SSRIs) in the treatment
of acute COVID-19 is still under investigation, with conflicting results reported from …

Background The recent global pandemic has placed a high priority on identifying drugs to
prevent or lessen clinical infection of severe acute respiratory syndrome coronavirus 2 …

The outbreak of a novel human coronavirus (SARS-CoV-2) has evolved into global health
emergency, infecting hundreds of thousands of people worldwide. In an effort to find antiviral …